2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2604

Pain Chronification and the Important Role of Non-disease Specific Symptoms in Patients with Systemic Sclerosis
Abstract Number: 2845

Pain Patterns in Idiopathic Inflammatory Myopathy (IIM): Associations with Disease Activity Measures (Muscle Enzymes, Manual Muscle Testing 8), Patient-Reported Quality of Life (HAQ) and Pain Scales (Widespread Pain Index (WPI), Symptom Severity Index (SSI) and Visual Analogue Scale)
Abstract Number: 628

Pain Perception and Opiate Use Among Patients with Inflammatory Arthritis
Abstract Number: 153

Palliative Care Curriculum in Rheumatology: Teaching Serious Illness Conversations
Abstract Number: 301

PANLAR Ultrasound Study Group Recommendations for the Use of Imaging in the Management of Patients with Gout
Abstract Number: 3

Pannexin-1 KO Mice Are Unresponsive to Tenofovir Induced Bone Loss
Abstract Number: 1053

Parallel Analysis of Systemic Sclerosis and Keloidal Morphea Skin Biopsies Delineates the Hallmark Profibrotic Gene Expression Profile for Scleroderma in Vivo
Abstract Number: 2842

Paraoxonase 1 Activity Is Abnormal in Patients with Idiopathic Inflammatory Myopathies and Associates with Poor Disease Control
Abstract Number: 2241

Parent Perspectives on Addressing Emotional Health for Youth with Juvenile Myositis: A Qualitative Focus Group Study
Abstract Number: 1921

Parent-Reported Medication Side-Effects and Their Impact on Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Abstract Number: 2224

Parkinson’s Disease and Risk of Fractures : A Meta Analysis of Cohort Studies
Abstract Number: 274

Participation in the Stanford University Chronic Pain Self-Management Program in a Population with a High Prevalence of Arthritis
Abstract Number: 1462

Pathogenesis of Vaginal Dryness in Primary Sjögren’s Syndrome: A Histopathological Case-control Study
Abstract Number: 2257

Patient and Clinical Characteristics Associated with Increased Willingness to Adopt RA Treatment After an Educational Intervention: An Analysis of the Confident Treatment Decisions for Living with Rheumatoid Arthritis (CONTROL-RA) Trial
Abstract Number: 2256

Patient Beliefs and Perceptions of Methotrexate for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].